Kalbitor(ecallantide)
Kalbitor 10 MG in 1 mL Injection
Dosage & Administration
Dosage & Administration
drug label
Kalbitor Prescribing Information
financial assistance
Kalbitor Financial Assistance Options
patient education
Kalbitor Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
people also ask
Kalbitor FAQs
1. Is it safe to use KALBITOR during pregnancy?Available data from the pharmacovigilance database for KALBITOR have not indicated a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies showed some effects on fetal development in rats at higher doses, but no such effects were observed in rabbits. The estimated background risk of major birth defects and miscarriage in the general population is 2% to 4% and 15% to 20%, respectively.
2. What do we know about KALBITOR use during lactation?There is no data available on the presence of ecallantide (KALBITOR) in human milk, its effects on the breastfed infant, or its impact on milk production. When considering the use of KALBITOR, the potential benefits of breastfeeding for the infant's development and health should be weighed against the mother's clinical need for KALBITOR, while also assessing potential adverse effects on the breastfed child from KALBITOR or the maternal condition.
3. Is KALBITOR safe for use in pediatric patients?The safety and effectiveness of KALBITOR have been established in patients aged 12 to 17 years. The safety profile observed in pediatric patients aged 12-17 years was similar to the adverse reactions observed in the overall clinical trial population. However, the safety and effectiveness of KALBITOR have not been established in patients less than 12 years of age.
4. Is KALBITOR suitable for use in geriatric patients?Clinical trials of KALBITOR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, taking into account the higher likelihood of decreased hepatic, renal, or cardiac function, and the presence of concomitant diseases or other drug therapy.
FAQ Data Source